Resources

Dr. Stanley Schwartz talks about his groundbreaking presentation at the 2014 ADA in which he outlined a new approach to classifying diabetes based on the health of the patient’s beta-cells. He explains in detail here how the current system of classification is full of contradictions and overlap between different types …

Dr. Stanley Schwartz talks about choosing the right drugs for each individual patient, and which ones should be first tier choices, which ones second, and the efficacy we should be looking for from them….   More videos in this series with Dr. Schwartz Stanley Schwartz, MD, FACP, FACE: Introduction, ADA …

Dr. Stanley Schwartz relates his overwhelmingly positive experience treating patients with newer drug therapies such as GLP-1 agonists and SGLT-2 inhibitors. He explains that he will sometimes put patients, on the very first day of their visit, on these medications when their A1c’s are very high and, one month later, …

Dr. Stanley Schwartz talks about why he doesn’t think that sulfonylureas should be used any longer, emphasizing that although they were useful when there were no alternatives, there are far safer and better drugs available today. More videos in this series with Dr. Schwartz Stanley Schwartz, MD, FACP, FACE: Introduction, …

Dr. Stanley Schwartz talks about the best way to determine beta cell function and says that there are actually several indicators that might need to be used. He suggests that there may be several steps that need to be taken including genotyping patients, looking at both classic markers and newer …

Dr. Stanley Schwartz talks about addressing the epidemic of not only diabetes but the growing numbers of prediabetes patients. He reviews the current policy situation and then talks about how he proceeds in his practice with prediabetes patients.  He points out that several studies have shown that adding certain medications …

  Dr. Stanley Schwartz addresses the question of, “Where do we go from here?” regarding the beta-cell centric approach. He notes that there are two ways to approach the question — grassroots and a top-down approach — and says that both avenues should be pursued. He hopes that his his …

In this second set of Homerun Slides focusing on Type 1 Diabetes and Psychoeducation, we review the emotions that both children and parents may experience after an initial diagnosis and some of the challenges that both face in managing a child’s type 1 diabetes… To download the complete set of …

I was reviewing a client’s insulin administration. She was administering Levemir (insulin detemir), 60 units, with a FlexPen. She said that she just dialed the dose to the maximum it would allow her as she knew it only would dial to 60 units. She did not confirm the dose visually. Although …

Rudy Bilous, MD, FRCP Richard Donnelly, MD, PHD, FRCP, FRACP Diabetic ketoacidosis (DKA) is a state of severe uncontrolled diabetes caused by insulin deficiency. It is characterised by hyperglycaemia, hyperketonaemia and metabolic acidosis, and has been somewhat arbitrarily divided into mild, moderate and severe based upon biochemical and clinical features (Table 12.1)….